Abstract
The low-density lipoprotein cholesterol (LDL-C) is established as a causative agent of atherosclerotic
cardiovascular disease (ASCVD) and lowering plasma LDL-C levels represents the main approach to
reduce the risk of cardiovascular events. Statins remain the cornerstone of drug therapy for dyslipidemia.
Although moderate- to high- intensity statin therapy has demonstrated consistent benefits for secondary
prevention of cardiovascular events, statin monotherapy is insufficient to achieve the guideline-recommended
LDL-C levels for high- and very high-risk patients. Some patients cannot tolerate statins, especially when taking
long-term high doses. Several non-statin drugs that have a complementary mechanism of action to statins
are now available, including ezetimibe, monoclonal antibodies targeted to proprotein convertase subtilisin/
kexin type 9 (PCSK9 mAb), and, more recently, inclisiran, bempedoic acid, and evinacumab. Considering the
recommendations from guidelines by domestic and international cardiovascular associations, combining
these drugs should be contemplated to attain treatment goals for patients.
| Published | 2023-12-31 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 13 No. 6 (2023) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2023.6.1 | |
| Keywords | suicidal ideation, adolescents, separation/divorce suicidal ideation, adolescents, separation/divorce |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Medicine and Pharmacy
Reiner Z., Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014; 24(10):1057-66.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1):111-188.
Mercep I, Strikic D, Sliskovic AM, Reiner Z. New Therapeutic Approaches in Treatment of Dyslipidaemia-A Narrative Review. Pharmaceuticals (Basel). 2022;15(7).
Bardolia C, Amin NS, Turgeon J. Emerging Non-statin Treatment Options for Lowering Low Density Lipoprotein Cholesterol. Front Cardiovasc Med. 2021; 8:789931.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018. 379(22): 2097-2107.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med.2017;376(18):1713-22.
Sun J, Lepor NE, Canton G, Contreras L, Hippe DS, Isquith DA, et al. Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab. Int J Cardiovasc Imaging. 2021;37(4):1415-22.
Lepor NE, Sun J, Canton G, Contreras L, Hippe DS, Isquith DA, et al. Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study. Atherosclerosis. 2021;327:31-8.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337.
Pearson, G.J., et al., 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol, 2021. 37(8): p. 1129-1150.
Writing C, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL- Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-418.
Vietnam National Heart Association. Khuyến cáo về dự phòng bệnh lý tim mạch trong thực hành lâm sàng. 2022:37-9.
Mercep I, Friscic N, Strikic D, Reiner Z. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review. Cardiovasc Ther. 2022;2022:8129513.
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(8):711-20.
Muscoli S, Ifrim M, Russo M, Candido F, Sanseviero A, Milite M, et al. Current Options and Future Perspectives in the Treatment of Dyslipidemia. J Clin Med. 2022;11(16).
Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA. 2022;327(17):1679-87.
Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401-12.
Stein EAT, T.A.; Kereiakes, D.J.; Butcher, B.; Mangu, P.; Zhou, R. Safety, Tolerability and LDL-C Reduction With LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open- Label Extension Phase 2B Study. Circulation. 2019;140.
Momtazi-Borojeni AA, Jaafari MR, Banach M, Gorabi AM, Sahraei H, Sahebkar A. Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates. Vaccines (Basel). 2021;9(7).
Momtazi-Borojeni AA, Jaafari MR, Badiee A, Sahebkar A. Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. Atherosclerosis. 2019;283:69-78.